These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23809402)

  • 1. Severe sleepiness and excess sleep duration induced by paroxetine treatment is a beneficial pharmacological effect, not an adverse reaction.
    Murata Y; Kamishioiri Y; Tanaka K; Sugimoto H; Sakamoto S; Kobayashi D; Mine K
    J Affect Disord; 2013 Sep; 150(3):1209-12. PubMed ID: 23809402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome.
    Murata Y; Kobayashi D; Imuta N; Haraguchi K; Ieiri I; Nishimura R; Koyama S; Mine K
    J Clin Psychopharmacol; 2010 Feb; 30(1):11-7. PubMed ID: 20075642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea.
    Tanaka M; Kobayashi D; Murakami Y; Ozaki N; Suzuki T; Iwata N; Haraguchi K; Ieiri I; Kinukawa N; Hosoi M; Ohtani H; Sawada Y; Mine K
    Int J Neuropsychopharmacol; 2008 Mar; 11(2):261-7. PubMed ID: 17697394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.
    Kato M; Ikenaga Y; Wakeno M; Okugawa G; Nobuhara K; Fukuda T; Fukuda K; Azuma J; Kinoshita T
    Int Clin Psychopharmacol; 2005 May; 20(3):151-6. PubMed ID: 15812265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of CYP2D6*10 on H1-antihistamine-induced hypersomnia.
    Saruwatari J; Matsunaga M; Ikeda K; Nakao M; Oniki K; Seo T; Mihara S; Marubayashi T; Kamataki T; Nakagawa K
    Eur J Clin Pharmacol; 2006 Dec; 62(12):995-1001. PubMed ID: 17089107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
    Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.
    Nishimura M; Ueda M; Saruwatari J; Nakashima H; Ogusu N; Aoki A; Tsuchimine S; Matsuda K; Iwashita K; Ono T; Oniki K; Shimoda K; Yasui-Furukori N
    Pharmacogenet Genomics; 2016 Sep; 26(9):403-13. PubMed ID: 27187662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin transporter polymorphism and bleeding time during SSRI therapy.
    Hougardy DM; Egberts TC; van der Graaf F; Brenninkmeijer VJ; Derijks LJ
    Br J Clin Pharmacol; 2008 May; 65(5):761-6. PubMed ID: 18279474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paroxetine: a review of clinical experience.
    Dunner D; Kumar R
    Pharmacopsychiatry; 1998 May; 31(3):89-101. PubMed ID: 9657236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia.
    Stedman CA; Begg EJ; Kennedy MA; Roberts R; Wilkinson TJ
    Hum Psychopharmacol; 2002 Jun; 17(4):187-90. PubMed ID: 12404686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response.
    Gex-Fabry M; Eap CB; Oneda B; Gervasoni N; Aubry JM; Bondolfi G; Bertschy G
    Ther Drug Monit; 2008 Aug; 30(4):474-82. PubMed ID: 18641553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin syndrome - 'potential' role of the CYP2D6 genetic polymorphism in Asians.
    Kaneda Y; Kawamura I; Fujii A; Ohmori T
    Int J Neuropsychopharmacol; 2002 Mar; 5(1):105-6. PubMed ID: 12057035
    [No Abstract]   [Full Text] [Related]  

  • 13. Relationship between CYP 2D6 metabolic status and sexual dysfunction in paroxetine treatment.
    Zourková A; Hadasová E
    J Sex Marital Ther; 2002; 28(5):451-61. PubMed ID: 12378847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder.
    Ruhé HG; Ooteman W; Booij J; Michel MC; Moeton M; Baas F; Schene AH
    Pharmacogenet Genomics; 2009 Jan; 19(1):67-76. PubMed ID: 18987562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversible hepatotoxicity of paroxetine in a patient with major depression.
    Helmchen C; Boerner RJ; Meyendorf R; Hegerl U
    Pharmacopsychiatry; 1996 Nov; 29(6):223-6. PubMed ID: 8956353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects.
    Zourková A; Hadasová E
    Gen Physiol Biophys; 2003 Mar; 22(1):103-13. PubMed ID: 12870705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation syndrome associated with paroxetine in depressed patients: a retrospective analysis of factors involved in the occurrence of the syndrome.
    Himei A; Okamura T
    CNS Drugs; 2006; 20(8):665-72. PubMed ID: 16863271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy.
    Ververs FF; Voorbij HA; Zwarts P; Belitser SV; Egberts TC; Visser GH; Schobben AF
    Clin Pharmacokinet; 2009; 48(10):677-83. PubMed ID: 19743889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease.
    Roose SP; Laghrissi-Thode F; Kennedy JS; Nelson JC; Bigger JT; Pollock BG; Gaffney A; Narayan M; Finkel MS; McCafferty J; Gergel I
    JAMA; 1998 Jan; 279(4):287-91. PubMed ID: 9450712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.